RenovoRx Financials

RNXT Stock  USD 1.00  0.01  1.01%   
Based on the key measurements obtained from RenovoRx's financial statements, RenovoRx may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, RenovoRx's Total Current Liabilities is comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 9.8 M in 2025, despite the fact that Total Stockholder Equity is likely to grow to (3.3 M). Key indicators impacting RenovoRx's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio1.071.12
Sufficiently Down
Very volatile
The essential information of the day-to-day investment outlook for RenovoRx includes many different criteria found on its balance sheet. An individual investor should monitor RenovoRx's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in RenovoRx.

Net Income

(9.67 Million)

  
Please note, the imprecision that can be found in RenovoRx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RenovoRx. Check RenovoRx's Beneish M Score to see the likelihood of RenovoRx's management manipulating its earnings.

RenovoRx Stock Summary

RenovoRx competes with Adial Pharmaceuticals, Pasithea Therapeutics, Quoin Pharmaceuticals, Nutriband, and Longeveron LLC. RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Renovorx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS75989R1077
CUSIP75989R107
LocationCalifornia; U.S.A
Business Address4546 El Camino
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websiterenovorx.com
Phone650 284 4433
CurrencyUSD - US Dollar

RenovoRx Key Financial Ratios

RenovoRx Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets1.9M16.3M7.3M1.5M1.7M1.6M
Other Current Liab1.2M413K568K614K706.1K666.4K
Net Debt995K(15.2M)(6.4M)(1.2M)(1.1M)(1.1M)
Retained Earnings(15.0M)(21.3M)(31.2M)(41.4M)(37.3M)(39.1M)
Accounts Payable162K525K534K561K645.2K510.4K
Cash1.8M15.2M6.4M1.2M1.3M1.3M
Other Current Assets115K1.1M825K293K337.0K542.1K
Total Liab16.6M938K1.1M4.5M4.0M5.8M
Net Invested Capital(11.9M)15.3M6.2M(3M)(3.5M)(3.3M)
Total Current Assets1.9M16.3M7.3M1.5M1.7M1.6M
Net Working Capital(2.2M)15.3M6.2M291K334.7K317.9K

RenovoRx Key Income Statement Accounts

The reason investors look at the income statement is to determine what RenovoRx's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Net Interest Income(587K)(834K)57K111K127.7K134.0K
Interest Expense590K834K57K108K97.2K92.3K
Operating Income(3.2M)(5.7M)(10.0M)(11.4M)(10.3M)(10.8M)
Ebit(6.4M)(5.7M)(10.0M)(11.4M)(10.3M)(10.8M)
Research Development2.4M3.0M4.3M5.7M6.5M4.0M
Ebitda(3.2M)(5.7M)(9.9M)(11.4M)(10.3M)(10.8M)
Income Before Tax(3.8M)(6.3M)(9.9M)(10.2M)(9.2M)(9.7M)
Net Income(4.4M)(7.1M)(9.8M)(10.2M)(9.2M)(9.7M)
Income Tax Expense587K772K(118K)(6.0)(5.4)(5.13)

RenovoRx Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash(329K)13.4M(10.8M)(3.2M)(2.9M)(2.8M)
Free Cash Flow(3.5M)(5.9M)(8.8M)(10.3M)(9.2M)(9.7M)
Other Non Cash Items489K697K647K(1.7M)(1.5M)(1.5M)
Net Income(3.8M)(6.3M)(9.9M)(10.2M)(9.2M)(9.7M)
End Period Cash Flow1.8M15.2M4.4M1.2M1.3M1.3M

RenovoRx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining RenovoRx's current stock value. Our valuation model uses many indicators to compare RenovoRx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across RenovoRx competition to find correlations between indicators driving RenovoRx's intrinsic value. More Info.
RenovoRx is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, RenovoRx's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value RenovoRx by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

RenovoRx Systematic Risk

RenovoRx's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. RenovoRx volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on RenovoRx correlated with the market. If Beta is less than 0 RenovoRx generally moves in the opposite direction as compared to the market. If RenovoRx Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one RenovoRx is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of RenovoRx is generally in the same direction as the market. If Beta > 1 RenovoRx moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in RenovoRx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various RenovoRx's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of RenovoRx growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.26

At this time, RenovoRx's Price Earnings To Growth Ratio is comparatively stable compared to the past year.

RenovoRx March 18, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of RenovoRx help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of RenovoRx. We use our internally-developed statistical techniques to arrive at the intrinsic value of RenovoRx based on widely used predictive technical indicators. In general, we focus on analyzing RenovoRx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build RenovoRx's daily price indicators and compare them against related drivers.

Additional Tools for RenovoRx Stock Analysis

When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.